Mr Marcus Drake Consultant urological surgeon

Background

Marcus Drake is professor of neurological urology at Imperial College London, and honorary consultant urologist at Charing Cross Hospital. His clinical interests in urology are urodynamics, neuro-urology, lower urinary tract symptoms (LUTS) and nocturia. He is lead or co-lead investigator of UK National Institute of Health Research grants in male LUTS (UPSTREAM, TRIUMPH, PLANET and PREMISE), a US NIH grant in physiology (PDE5 effects on voiding), the newly-designed “Flume” urinary catheter (RfPB funded) and urinary tract infection diagnostics (i4i QUICK). His total cumulative grant awards are £33M, of which £10M are as CI. He is a trustee of the International Continence Society. He is member of NICE panels (recurrent UTIs and male LUTS guideline groups, intermittent catheters late stage assessment). He was chairman of the International Continence Society’s Standardisation Steering Committee, and board member of the European School of Urology and the European Society of Female and Functional Urology. He was a member of the European Association of Urology Guidelines committees for male LUTS and female incontinence. He has published major books, including the 4th edition of “Abrams’ Urodynamics” and “Medicine in a Day” volumes 1 and 2.

 

 

Expertise

Neuro-urology and functional urology

Research & publications

1. Moving Beyond the Bladder Diary: Does New Technology Now Allow Us to Take Investigation of LUTS Into the Community? ICI-RS 2024.
Drinnan M, Abrams P, Arlandis S, Drake MJ, Gammie A, Harding C, Rantell A, Valentini F. Neurourol Urodyn. 2024 Dec 27. doi: 10.1002/nau.25646.

2. Can We Prevent Recurrent UTIs Without Antibiotics, in Both Those Who Do and Do Not Use Catheters? ICI-RS 2024. Harding C, Clavica F, Averbeck MA, Da Silva A, Drake MJ, Gajewski JB, Khullar V, Pozniak M, Rantell AM, Tarcan T, Werneburg GT, Giarenis I. Neurourol Urodyn. 2024 Dec 24. doi: 10.1002/nau.25641.

3. Challenges in Urinary Tract Infection and the Ongoing Quest for Solutions. Drake MJ, Wagenlehner F. Eur Urol Focus. 2024 Sep;10(5):681-682. doi: 10.1016/j.euf.2024.10.001. Epub 2024 Oct 12. PMID: 39396892

4. Bidirectional relationships between depression, anxiety and urinary symptoms in women: A prospective cohort study. Joinson C, Drake MJ, Fraser A, Tilling K, Heron J. J Affect Disord. 2025 Jan 15;369:516-522. doi: 10.1016/j.jad.2024.10.035. Epub 2024 Oct 10. PMID: 39393464

5. Interleukins in Urine and Blood as Markers of Infection and as Risk Factors for Systemic Conditions. Luxton R, Kiely J, Drake M. Eur Urol Focus. 2024 Sep;10(5):706-709. doi: 10.1016/j.euf.2024.09.016. Epub 2024 Oct 5. PMID: 39368920

6. Innovating Indwelling Catheter Design to Counteract Urinary Tract Infection. Drake MJ, Clavica F, Murphy C, Fader MJ. Eur Urol Focus. 2024 Sep;10(5):713-719. doi: 10.1016/j.euf.2024.09.015. Epub 2024 Sep 28. PMID: 39341718

7. Beyond Surgery: Navigating Postoperative Care for Cauda Equina Syndrome Through a Scoping Review. Anil K, Olmesdahl-Fletcher S, Read J, Hughes S, Drake MJ, Hoeritzauer I, Woodfield J, Roy H. World Neurosurg. 2024 Dec;192:216-223.e4. doi: 10.1016/j.wneu.2024.09.081. Epub 2024 Oct 16. PMID: 39326664

8. Towards a Reference Standard Definition of Urinary Tract Infection for Research. Werneburg GT, Wagenlehner F, Clemens JQ, Harding C, Drake MJ. Eur Urol Focus. 2024 Sep 24:S2405-4569(24)00178-0. doi: 10.1016/j.euf.2024.09.010. Online ahead of print. PMID: 39322455

9. The Urinary Microbiome Is a Potential Driver of Urinary Tract Pathology Through Multiple Mechanisms Including Deglucuronidation and DNA Damage. Marchesi JR, Drake MJ. Eur Urol Focus. 2024 Sep;10(5):683-685. doi: 10.1016/j.euf.2024.08.009. Epub 2024 Sep 3. PMID: 39232906

10. Re: Peroperative urodynamics still has a role for BPH patients after the UPSTREAM trial. Drake MJ. Fr J Urol. 2024 Sep;34(9):102677. doi: 10.1016/j.fjurol.2024.102677. Epub 2024 Jul 9. PMID: 38992729

11. High-Performance Dopamine-Based Supramolecular Bio-Adhesives. Hagemann MJL, Chadwick L, Drake MJ, Hill DJ, Baker BC, Faul CFJ.
Macromol Rapid Commun. 2024 Dec;45(23):e2400345. doi: 10.1002/marc.202400345. Epub 2024 Jun 6. PMID: 38760014

12. Bladder Outlet Obstruction Relief and Symptom Improvement Following Medical and Surgical Therapies for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Systematic Review. Creta M, Russo GI, Bhojani N, Drake MJ, Gratzke C, Peyronnet B, Roehrborn C, Tikkinen KAO, Cornu JN, Fusco F. Eur Urol. 2024 Oct;86(4):315-326. doi: 10.1016/j.eururo.2024.04.031. Epub 2024 May 14. PMID: 38749852

13. Re: EV-301 Long-term Outcomes: 24-month Findings from the Phase III Trial of Enfortumab Vedotin Versus Chemotherapy in Patients with Previously Treated Advanced Urothelial Carcinoma. Drake MJ, Birder LA. Eur Urol. 2024 Aug;86(2):183-184. doi: 10.1016/j.eururo.2024.03.011. Epub 2024 Mar 26. PMID: 38538426

14. Lower urinary tract symptoms in men: the TRIUMPH cluster RCT. Worthington J, Frost J, Sanderson E, Cochrane M, Wheeler J, Cotterill N, MacNeill SJ, Noble S, Avery M, Clarke S, Fader M, Hashim H, McGeagh L, Macaulay M, Rees J, Robles L, Taylor G, Taylor J, Thompson J, Lane JA, Ridd MJ, Drake MJ; TRIUMPH study group. Health Technol Assess. 2024 Mar;28(13):1-162. doi: 10.3310/GVBC3182.PMID: 38512051

15. Cost-effectiveness of a prima